In the current study, we found that GC patients with high ANTXR1 expression tumors have lower TMB, which indicated that patients with low ANTXR1 expression may be more sensitive to immune checkpoint inhibitor therapy. This evidence concerns the gene ANTXR1 and gastric cancer.